A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) (NCT06911502)

🧪 Interventions in This Study

• Golcadomide (DRUG)
• Rituximab (DRUG)
• Lenalidomide (DRUG)
• Cyclophosphamide (DRUG)
• Doxorubicin (DRUG)
• Vincristine (DRUG)
• Prednisone/Prednisolone (DRUG)
• Bendamustine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (160 Sites)

Showing the first 25 of 160 sites.

• Local Institution - 0225 — Birmingham, Alabama
• Infirmary Cancer Care — Mobile, Alabama
• Alaska Oncology and Hematology — Anchorage, Alaska
• Local Institution - 0215 — Little Rock, Arkansas
• City of Hope Comprehensive Cancer Center — Duarte, California
• UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
• Local Institution - 0008 — Jacksonville, Florida
• Local Institution - 0214 — Tampa, Florida
• Local Institution - 0217 — Tampa, Florida
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
• Southeastern Regional Medical Center — Newnan, Georgia
• Local Institution - 0240 — Arlington Heights, Illinois
• Local Institution - 0253 — Iowa City, Iowa
• Local Institution - 0243 — Waukee, Iowa
• Local Institution - 0216 — Westwood, Kansas
• Local Institution - 0218 — Lexington, Kentucky
• Local Institution - 0023 — Baltimore, Maryland
• Greater Baltimore Medical Center — Towson, Maryland
• Local Institution - 0145 — Boston, Massachusetts
• Local Institution - 0244 — Boston, Massachusetts
• Local Institution - 0247 — Boston, Massachusetts
• Hattiesburg Clinic Hematology/Oncology — Hattiesburg, Mississippi
• Local Institution - 0144 — Providence, Rhode Island
• Texas Oncology - Central/South Texas — Austin, Texas
• Local Institution - 0212 — Fort Worth, Texas

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Follicular Lymphoma

• A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
• Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
• Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
• Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California

Explore by condition: All Follicular Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.